Floatz logo

Bcma Car T Cells

Amyloidosis

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
fx-1006a
Pfizer
Phase 4BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB

View all 38 →

Same molecule, other indications

Bcma Car T Cells is also rated in:

POEMS syndromeDormant
C
Indicative ·
39 / 100
View asset →
autoimmune hemolytic anemiaDormant
C
Indicative ·
39 / 100
View asset →
vasculitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →